Nuwellis(NUWE)2025-05-13 15:00Revenue and Financial Performance - Revenue for Q1 2025 was $1.9 million, a 3% increase compared to Q1 2024[3] - Gross margin for Q1 2025 was 56.0%, down from 64.1% in the prior-year quarter[4] - Operating loss improved to $3.1 million in Q1 2025, compared to a loss of $4.7 million in Q1 2024[7] - Net loss attributable to common shareholders was $3.0 million, or a loss of $0.69 per share, compared to a net loss of $3.8 million, or $24.11 per share, in the prior-year period[8] Expenses - SG&A expenses decreased by 22% to $3.6 million from $4.6 million in Q1 2024[5] - R&D expenses were $550 thousand, a significant reduction from $1.3 million in the prior-year quarter[7] Cash Position - As of March 31, 2025, cash and cash equivalents were $2.6 million, with no debt[9] Market and Reimbursement - Effective January 1, 2025, CMS increased the outpatient reimbursement rate for Aquadex nearly four-fold to $1,639 per day[6] - The company is focusing on expanding outpatient opportunities driven by favorable reimbursement and clinical data[6] Utilization and Growth - Consumables utilization grew by 4% year-over-year, with pediatric revenue increasing by 38%[6]